ELZONRIS (tagraxofusp-erzs)
ANTINEOPLASTIC - CD123-DIRECTED CYTOTOXIN CONJUGATE · BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
STEMLINE THERAP
Drug class
Antineoplastic - CD123-Directed Cytotoxin Conjugate
Antineoplastic CD123-directed cytotoxin conjugates represent a targeted class of therapeutic agents, exemplified by recombinant fusion proteins such as tagraxofusp. Read more about Antineoplastic - CD123-Directed Cytotoxin Conjugate
2 drugs in this class 2 manufacturers
Drugs in Antineoplastic - CD123-Directed Cytotoxin Conjugate
DECNUPAZ (pivekimab sunirine-pvzy)
ANTINEOPLASTIC - CD123-DIRECTED CYTOTOXIN CONJUGATE · BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
ABBOTT
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - CD123-Directed Cytotoxin Conjugate preselected. Add indication or manufacturer filters there.
Antineoplastic CD123-directed cytotoxin conjugates represent a targeted class of therapeutic agents, exemplified by recombinant fusion proteins such as tagraxofusp.
These agents are engineered by linking a CD123-targeting domain, such as human interleukin-3, to a cytotoxic payload like truncated diphtheria toxin.
Once the molecule binds to CD123 on malignant cells, it undergoes receptor-mediated endocytosis, releasing the toxin to inhibit intracellular protein synthesis and trigger cell apoptosis.
The primary therapeutic application is in hematologic malignancies characterized by high CD123 expression, predominantly blastic plasmacytoid dendritic cell neoplasm, with ongoing evaluation in related myeloid cancers.
-
fda.gov
Antineoplastic CD123-directed cytotoxin conjugates represent a targeted class of therapeutic agents, exemplified by recombinant fusion proteins such as tagraxofusp
-
nih.gov
Antineoplastic CD123-directed cytotoxin conjugates represent a targeted class of therapeutic agents, exemplified by recombinant fusion proteins such as tagraxofusp These agents are engineered by linking a CD123-targeting domain, such as human interleukin-3, to a cytotoxic payload like truncated diphtheria toxin
-
elzonris.com
These agents are engineered by linking a CD123-targeting domain, such as human interleukin-3, to a cytotoxic payload like truncated diphtheria toxin Once the molecule binds to CD123 on malignant cells, it undergoes receptor-mediated endocytosis, releasing the toxin to inhibit intracellular protein synthesis and trigger cell apoptosis
-
nih.gov
Once the molecule binds to CD123 on malignant cells, it undergoes receptor-mediated endocytosis, releasing the toxin to inhibit intracellular protein synthesis and trigger cell apoptosis
-
dana-farber.org
The primary therapeutic application is in hematologic malignancies characterized by high CD123 expression, predominantly blastic plasmacytoid dendritic cell neoplasm, with ongoing evaluation in related myeloid cancers
-
nih.gov
The primary therapeutic application is in hematologic malignancies characterized by high CD123 expression, predominantly blastic plasmacytoid dendritic cell neoplasm, with ongoing evaluation in related myeloid cancers
-
fda.gov
The primary therapeutic application is in hematologic malignancies characterized by high CD123 expression, predominantly blastic plasmacytoid dendritic cell neoplasm, with ongoing evaluation in related myeloid cancers
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.